KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2018 - 2020)

Ionis Pharmaceuticals has reported Long-Term Deferred Tax over the past 5 years, most recently at $307.7 million for Q3 2020.

  • Quarterly results put Long-Term Deferred Tax at $307.7 million for Q3 2020, up 7.98% from a year ago — trailing twelve months through Sep 2020 was $307.7 million (up 7.98% YoY), and the annual figure for FY2019 was $305.6 million, up 5.08%.
  • Long-Term Deferred Tax for Q3 2020 was $307.7 million at Ionis Pharmaceuticals, up from $306.0 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for IONS hit a ceiling of $309.6 million in Q1 2020 and a floor of $276.4 million in Q2 2019.
  • Median Long-Term Deferred Tax over the past 3 years was $298.2 million (2018), compared with a mean of $294.8 million.
  • Biggest five-year swings in Long-Term Deferred Tax: rose 5.08% in 2019 and later increased 11.67% in 2020.
  • Ionis Pharmaceuticals' Long-Term Deferred Tax stood at $290.8 million in 2018, then increased by 5.08% to $305.6 million in 2019, then grew by 0.71% to $307.7 million in 2020.
  • The last three reported values for Long-Term Deferred Tax were $307.7 million (Q3 2020), $306.0 million (Q2 2020), and $309.6 million (Q1 2020) per Business Quant data.